Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
184,457
clinical trials

Lennox Gastaut Syndrome Clinical Trial
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lennox Gastaut Syndrome Clinical Trial
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Lennox Gastaut Syndrome Clinical Trial
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Nicklaus Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Lennox Gastaut Syndrome Clinical Trial
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
Status: Enrolling, Phase III
Updated: 12/31/1969
Minnesota Epilepsy Group
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Atopic Dermatitis Clinical Trial
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
Status: Enrolling, Phase IV
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Atopic Dermatitis Clinical Trial
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
Status: Enrolling, Phase IV
Updated: 12/31/1969
Ohio Pediatric Research Association, Inc
mi
from
Dayton, OH
Click here to add this to my saved trials
Atopic Dermatitis Clinical Trial
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
Status: Enrolling, Phase IV
Updated: 12/31/1969
Clinical Research Partners
mi
from
Richmond, VA
Click here to add this to my saved trials
HIV INfections Clinical Trial
Get Connected Efficacy Trial
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Prostate Carcinoma Clinical Trial
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
Avera Research Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Heart Failure Clinical Trial
REmodeling the Left Ventricle With Atrial Modulated Pacing
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Heart Failure Clinical Trial
REmodeling the Left Ventricle With Atrial Modulated Pacing
Status: Enrolling
Updated: 12/31/1969
The Lindner Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Heart Failure Clinical Trial
REmodeling the Left Ventricle With Atrial Modulated Pacing
Status: Enrolling
Updated: 12/31/1969
The University of Arizona Sarver Heart Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Munroe Regional Medical Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Clearwater Cardiovascular & Interventional Consultants, MD, PA
mi
from
Clearwater, FL
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Cardiovascular Associates Research LLC
mi
from
Covington, LA
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Moses Cone
mi
from
Greensboro, NC
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KS
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Wellmont Holston Valley Medical
mi
from
Kingsport, TN
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
University of Toledo Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Greenville Health System
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Rheumatology Clinical Trial
2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Type 1 Diabetes Mellitus Clinical Trial
Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Pneumonia Clinical Trial
ePneumonia: Development of an Electronic Clinical Decision Support System for Community-Onset Pneumonia
Status: Enrolling, Phase
Updated: 12/31/1969
Logan Regional Hospital
mi
from
Logan, UT
Click here to add this to my saved trials
Awareness Training Clinical Trial
Refinement and Validation of an Awareness Training Program
Status: Enrolling
Updated: 12/13/2017
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Neurology, Psychiatry / Psychology, Orthopedics / Podiatry, Other Clinical Trial
Treatment of Sleep-disordered Breathing in Patients With SCI
Status: Enrolling
Updated: 12/31/1969
John D. Dingell VA Medical Center, Detroit, MI
mi
from
Detroit, MI
Click here to add this to my saved trials
Clinical Trial
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Status: Enrolling, Phase II
Updated: 11/29/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Hypertrophic Scar Clinical Trial
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
Status: Enrolling, Phase I, II
Updated: 11/29/2017
Wcct Global, Llc
mi
from
Cypress, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
Status: Enrolling, Phase
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
Status: Enrolling, Phase
Updated: 12/31/1969
Gundersen Health System
mi
from
La Crosse, WI
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Status: Enrolling, Phase II
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Status: Enrolling, Phase II
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Status: Enrolling, Phase II
Updated: 12/31/1969
Northwell Health/Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Sickle Cell Disease Clinical Trial
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Status: Enrolling, Phase II
Updated: 12/31/1969
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Cardiology / Vascular Diseases Clinical Trial
Pre-medication With Alfentanil vs Placebo During ECT
Status: Enrolling, Phase IV
Updated: 12/31/1969
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Peritoneal Cancer Clinical Trial
Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Machine Learning for Handheld Vascular Studies
Status: Enrolling, Phase
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Peter's Community Hospital
mi
from
Helena, MT
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
21st Century Oncology - Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Centerpoint Medical Center LLC
mi
from
Independence, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Community Cancer Center North
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Southeastern Medical Oncology Center-Jacksonville
mi
from
Jacksonville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Freeman Health System
mi
from
Joplin, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Heartland Hematology and Oncology
mi
from
Kearney, NE
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
First Dayton Cancer Care
mi
from
Kettering, OH
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Community Howard Regional Health
mi
from
Kokomo, IN
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Las Vegas Cancer Center-Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Lawrence Memorial Hospital
mi
from
Lawrence, KS
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Sky Ridge
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Saints Mary and Elizabeth Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Marietta Memorial Hospital
mi
from
Marietta, OH
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Middlesex Hospital
mi
from
Middletown, CT
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Ochsner Medical Center Jefferson
mi
from
New Orleans, LA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Newark Radiation Oncology
mi
from
Newark, OH
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Integris Southwest Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial GYN Plus
mi
from
Ooltewah, TN
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Midlands Community Hospital
mi
from
Papillion, NE
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Singing River Hospital
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
mi
from
Pekin, IL
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Radiation Oncology Associates
mi
from
Reno, NV
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Sutter Roseville Medical Center
mi
from
Roseville, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Sutter Medical Center Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Kootenai Cancer Clinic
mi
from
Sandpoint, ID
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Rockwood Clinic Cancer Treatment Center-Valley
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Missouri Baptist Outpatient Center-Sunset Hills
mi
from
Sunset Hills, MO
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Francis Hospital and Medical Center - Topeka
mi
from
Topeka, KS
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute-Twin Falls
mi
from
Twin Falls, ID
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Inspira Medical Center Vineland
mi
from
Vineland, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling, Phase II
Updated: 12/31/1969
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials